A major setback for Novo Nordisk: their stock plunges 13% as their weight loss drug falls short in a critical trial, failing to outshine Eli Lilly's rival medication.
In a significant development, Novo Nordisk's shares took a hit after the company announced that CagriSema, their highly anticipated weight loss drug, didn't live up to expectations. The drug's primary objective was to prove it was at least as effective as Eli Lilly's tirzepatide, but it couldn't match its rival's performance over an 84-week period. This news sent shockwaves through the market, causing a sharp decline in Novo Nordisk's stock price.
Eli Lilly's tirzepatide, the active component in Mounjaro and Zepbound, has already established its dominance in the U.S. prescription market, surpassing Novo Nordisk's semaglutide-based drugs, Ozempic and Wegovy. And now, with CagriSema's disappointing results, Novo Nordisk faces an uphill battle.
But here's where it gets controversial: despite the setback, Novo Nordisk remains optimistic about CagriSema's potential. The drug combines semaglutide with cagrilintide, a hormone that influences appetite. The company believes this unique combination could offer superior weight loss benefits compared to GLP-1 treatments alone. But is this wishful thinking, or is there solid evidence to support this claim?
In the trial, patients taking a 2.4 mg dose of CagriSema lost 23% of their body weight after 84 weeks, while those on a 15 mg dose of tirzepatide achieved a 25.5% weight loss. Novo Nordisk acknowledges the gap but argues that further trials with higher doses could unlock CagriSema's full potential. However, with the stock already down nearly 50% in 2025 and sales growth predictions declining for 2026, investors are left wondering if this optimism is justified.
This latest trial result adds to Novo Nordisk's challenges, as they grapple with increased competition, pricing pressures, and the impending loss of exclusivity for their key drugs. CEO Mike Doustdar's statement that the stock will likely decline further before recovering adds to the uncertainty.
And this is the part most people miss: while Eli Lilly's stock rose 3.5% in premarket trading, the real question is whether this success is sustainable. Can Eli Lilly maintain its lead, or will Novo Nordisk's future trials turn the tables? The pharmaceutical industry is notorious for its twists and turns, and only time will tell which company emerges as the long-term winner in this weight loss drug race.
